StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

Investment analysts at StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

Eiger BioPharmaceuticals has a 52-week low of $1.10 and a 52-week high of $43.35. The stock has a fifty day moving average of $4.77 and a two-hundred day moving average of $6.98. The firm has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.03 and a beta of 1.83.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.